secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001213900-24-015108
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed plans new U.S. Phase 3 oral insulin trial after subpopulation analysis; JV with HTIT with $70M investment
--------------------------------------------------------------------------------

- HTIT completed Phase 3 for oral insulin in China, in final regulatory approval; JV definitive agreement with $70M from HTIT, $20M from Oramed.
- Oramed to initiate new Phase 3 U.S. oral insulin trial later 2024 under differentiated protocol after FDA discussions; earlier Phase 3 missed endpoints.
- Scilex issued $101.875M secured note to Oramed at SOFR+8.5%; repayment began Dec 2023; warrants for 13M Scilex shares at $0.01.
- Acquired PeriTech film-forming technology for topical/dermatology; entered exclusive licensing deal for royalty on net sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024015108/0001213900-24-015108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024015108/ea0200197-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-015108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer